EFV versus ATV + RTV, both with ABC-3TC or TDF-FTC ACTG 5202

Slides:

Advertisements

Similar presentations

Single Pill HIV Regimens – Introducing the Quad Pedro Cahn, MD Jean-Pierre Routy, MD Calvin Cohen, MD.

Advertisements

Douglas T. Dieterich, Juergen K. Rockstroh, Kenneth E. Sherman, Nathalie Adda, Lisa Mahnke, Varun Garg, Shahin Gharakhanian, Scott McCallister, Vincente.

A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.

VIREAD (Tenofovir DF) Update. Viread Update  Pharmacokinetics  Safety & Tolerability  Efficacy  Virology.

TMC278 Update, 30th January 2009  C204 data  ECHO and THRIVE - Phase III studies  New TMC278 formulations Peter Williams Tibotec BVBA, Mechelen, Belgium.

Comparison of INSTI vs PI  FLAMINGO  GS  ACTG A5257.

NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC

1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Switch to RAL-containing regimen  Canadian Study  CHEER  Montreal Study  EASIER  SWITCHMRK  SPIRAL  Switch ER.

Switch NNRTI to NNRTI  Switch EFV to ETR –CNS toxicity study –Patient’s preference study.

Highlights of the 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC) September 14-17, 2003; Chicago, Illinois Selected and summarized.

A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142 Riddler S.A.,

The 2 nd International AIDS Society Conference on HIV Pathogenesis and Treatment July 13-16, 2003; Paris, France Selected and summarized by Douglas J.

Hit Hard, Hit Early: When to Treat and With What? Brian G. Gazzard, MD, Moderator Julio Montaner, MD Calvin J. Cohen, MD, MS.

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Antiretroviral targets in the viral life cycle Viral Replication and Drug targets.

Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects

Comparison of PI vs PI  ATV vs ATV/r BMS 089  LPV/r mono vs LPV/r + ZDV/3TCMONARK  LPV/r QD vs BIDM M A5073  LPV/r + 3TC vs LPV/r + 2 NRTIGARDEL.

Superior Outcome for Tenofovir DF (TDF), Emtricitabine (FTC) and Efavirenz (EFV) Compared to Fixed Dose Zidovudine/Lamivudine (CBV) and EFV in Antiretroviral.

FLAMINGO Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14c January 2014.

ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.

KLEAN Study: Fosamprenavir/Ritonavir Associated With Similar Efficacy and Safety as Lopinavir/Ritonavir SGC in Treatment- Naive Patients Slideset on: Eron.

Phase 3 Treatment-Naïve and Treatment-Experienced

Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial

Effects of Switching ZDV-3TC to TDF-FTC or ABC-3TC SWAP

RAL + MVC + DRV/r + TDF-FTC

Sofosbuvir-Velpatasvir (Epclusa)

Dolutegravir plus Rilpivirine as Maintenance Dual Therapy SWORD-1 and SWORD- 2: Design

TDF-FTC vs. ABC-3TC, each with Atazanavir + RTV or Efavirenz ACTG 5224s (Bone Effects): Study Design

Switch to PI/r + 3TC vs PI/r monotherapy

TDF-FTC QD + Raltegravir BID TDF-FTC QD + Lopinavir-ritonavir QD

Lopinavir-RTV + TDF-FTC versus Maraviroc + TDF-FTC for PEP MARAVI-PEP: Study Design

Etravirine in Treatment Experienced DUET-2 (TMC125-C216)

Switch from TDF-based to Elvitegravir-Cobicistat-TAF-FTC Study 109

On Demand PrEP for Men at High Risk for HIV IPERGAY

Switch to RPV-TDF-FTC from Ritonavir-boosted PI Regimen SPIRIT STUDY

Lopinavir-ritonavir mg BID (n = 354)

Etravirine versus Protease Inhibitor in ARV-Experienced TMC 125-C227

Switch to Etravirine from Efavirenz due to CNS Toxicity SSAT-029 STUDY

Switch from EFV plus ABC-3TC to EFV-TDF-FTC ROCKET-1 Trial

Switch RPV-TDF-FTC from NVP-Based Regimen NEAR-Rwanda Trial

Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5

From: Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1A Randomized Trial Ann Intern Med. 2011;154(7):

Once Daily Etravirine versus Efavirenz in Treatment-Naive SENSE Trial

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study

Dolutegravir + ABC-3TC and CSF HIV-1 RNA Levels ING Study

Etravirine in Treatment Experienced DUET-1 (TMC125-C206)

Atazanavir + ritonavir vs. Lopinavir-ritonavir CASTLE Study

Darunavir/r versus Other PIs in Treatment Experienced POWER 1 and 2

Saquinavir + RTV versus Lopinavir-RTV in Treatment-Naïve GEMINI Trial

Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II

LPV-RTV versus LPV-RTV + ZDV-3TC in Treatment-Naïve MONARK Trial

Switching the NRTI Backbone to Tenofovir DF-Emtricitabine TOTEM

Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses

Comparison of current lowest global price vs estimated generic price, for medicines for diseases with large international treatment programmes. Comparison.

Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals Susanna Naggie, Mark S. Sulkowski Gastroenterology

Boceprevir in Treatment Naive SPRINT-2

Next Generation Capsid Inhibitor: GS–CA1

Phase 3 Treatment Naïve and Treatment Experienced HIV Coinfection

Switch to DRV/r monotherapy

Comparison of NNRTI vs PI/r

Comparison of PI vs PI ATV vs ATV/r BMS 089

Comparison of NNRTI vs PI/r

Comparison of NNRTI vs PI/r

Comparison of PI vs PI ATV vs ATV/r BMS 089

Switch to ATV/r monotherapy

A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142 Riddler S.A.,

Comparison of NRTI combinations

Comparison of NRTI combinations

Figure 1. Rate of PDR in infants according to ARV exposure

Presentation transcript:

EFV versus ATV + RTV, both with ABC-3TC or TDF-FTC ACTG 5202

EFV versus ATV/r, both with ABC-3TC or TDF-FTC ACTG 5202: Study Design Study Design: ACTG 5202 Background: Randomized, phase 3b equivalence trial to evaluate open-label efavirenz against atazanavir + ritonavir, each with either double-blinded abacavir-lamivudine or tenofovir DF-emtricitabine, for initial treatment of HIV. Inclusion Criteria (n = 1857) - Age >16 - Antiretroviral-naive - No major resistance mutations Treatment Arms (all medications once daily) - EFV 600 mg + ABC-3TC 600-300 mg - ATV 300 mg + RTV 100 mg + ABC-3TC 600-300 mg - EFV 600 mg + TDF-FTC 300-200 mg - ATV 300 mg + RTV 100 mg + TDF-FTC 300-200 mg EFV + ABC-3TC (n = 465) ATV + RTV + ABC-3TC (n = 463) EFV + TDF-FTC (n=464) ATV + RTV + TDF-FTC (n=465) Source: Daar ES, et al. Ann Intern Med. 2011;154:445-56.

EFV versus ATV/r, both with ABC-3TC or TDF-FTC ACTG 5202: Results Week 48: Virologic Response Source: Daar ES, et al. Ann Intern Med. 2011;154:445-56.

EFV versus ATV/r, both with ABC-3TC or TDF-FTC ACTG 5202: Results Week 96: Free of Virologic Failure *Virologic failure = HIV RNA ≥1000 copies/mL between 16 and 24 weeks, or HIV RNA ≥200 copies/mL after 24 weeks. Source: Daar ES, et al. Ann Intern Med. 2011;154:445-56.

EFV versus ATV/r, both with ABC-3TC or TDF-FTC ACTG 5202: Results Week 48: Analysis of Lipids Source: Daar ES, et al. Ann Intern Med. 2011;154:445-56.

EFV versus ATV/r, both with ABC-3TC or TDF-FTC ACTG 5202: Results Week 48: Change in Creatinine Clearance Source: Daar ES, et al. Ann Intern Med. 2011;154:445-56.

EFV versus ATV/r with ABC-3TC or TDF-FTC ACTG 5202: Conclusions Conclusion: “Atazanavir plus ritonavir and efavirenz have similar antiviral activity when used with abacavir-lamivudine or tenofovir DF-emtricitabine.” Source: Daar ES, et al. Ann Intern Med. 2011;154:445-56.